الفهرس | Only 14 pages are availabe for public view |
Abstract Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and account for 90-95 per cent of all thyroid cancers. Its subtypes include papillary thyroid carcinoma (PTC), follicular thyroid carcinoma and Hürthle cell carcinoma. Patients with differentiated thyroid carcinoma have an excellent prognosis. The multimodal therapeutic approach is risk-adapted to achieve optimal treatment of differentiated thyroid cancer (DTC) and to minimize treatment-related morbidity. The treatment includes surgery (near-/total thyroidectomy) usually followed by remnant ablation using radioiodine according to the guidelines of the American Thyroid Association (ATA) and European Association of Nuclear Medicine (EANM). Risk factors and prognostic criteria for recurrent thyroid cancer differ from those of primary disease. Survival in primary well differentiated thyroid cancer is inversely related to both patient age and tumor size. The serum thyroglobulin (Tg) concentration is commonly used as a marker of thyroid tissue persistence/ recurrence after near-total thyroidectomy in patients with negative Tg-antibody titers, with recombinant human thyroid stimulating hormone (rhTSH)-stimulated Tg levels >2.5 ng/mL as the optimal level for future recurrence. We aimed to evaluate frequency and factors of recurrence of well differentiated thyroid carcinoma after optimized surgery. This is a prospective cohort study included 40 patients with recurrent well deferentiated thyroid carcinoma. |